TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Misoprostol Vaginal Insert for Induction of Labour

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* At term (37 to 42 weeks inclusive gestation).~* Aged 18 years or older.~* One previous full term delivery (at least 37 weeks gestation).~* Singleton pregnancy.~* Cephalic presentation (normal lie).~* Bishop score more than 6 as determined by MBS criteria.~* Uncomplicated pregnancy as judged by the physician.~* Written informed consent.~Exclusion Criteria:~* four previous full term deliveries.~* Previous uterine surgery, including C-section and surgery to the cervix of the uterus (cone biopsy of the cervix is permitted).~* In spontaneous labour.~* Administration of oxytocin or a tocolytic drug or any other cervical ripening or labour inducing agent prior to enrolment (within seven days of enrolment).~* Suspected cephalo-pelvic disproportion.~* Evidence or suggestion of fetal distress.~* Subject has received NSAID (including aspirin) within four hours of study treatment (topical is permitted).~* Pyrexia (oral or aural temperature \> 37.5C).~* Unexplained genital bleeding during this pregnancy after 24 weeks.~* Current pelvic inflammatory disease, unless adequate prior treatment has been instituted.~* Placenta praevia.~* Known or suspected allergy to misoprostol or other prostaglandins.~* Prior serious adverse event related to prostaglandin administered by any route for any indication.~* Subject unable to comply with the requirements of the protocol.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MVI 25 (Type: EXPERIMENTAL): Misoprostol vaginal insert 25 mcg
- MVI 50 (Type: EXPERIMENTAL): Misoprostol vaginal insert 50 mcg
- MVI 100 (Type: EXPERIMENTAL): Misoprostol vaginal insert 100 mcg
- MVI 200 (Type: EXPERIMENTAL): Misoprostol vaginal insert 200 mcg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Examining the Efficacy of Mattress Technology in Improving the Sleep Quality of Children With ASD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASD Diagnosis~* 2.5-12.99 Years of Age~* Sleep Difficulty as indicated by significant sleep disturbance on the Child Sleep Habits Questionnaire~* If participant is using medication or attends therapy, it must be stable four (4) weeks prior to their study participation and throughout the 5-6 week study period.~Exclusion Criteria:~* Age less than 2.5 years or more than 12.99 years~* Individuals who may have medication or therapy changes 4 weeks prior to study start date or during the study period~* An participant diagnosed with epilepsy, Fragile X, Downs Syndrome, seizure disorder, Neurofibromatosis, or Tuberous Sclerosis~* Any child with a pacemaker or other electrical device

- Gender: ALL
- Minimum Age: 30 Months
- Maximum Age: 13 Years
- Healthy Volunteers: f

Study Arms:
- Mattress Technology On then Off (Type: EXPERIMENTAL): Intervention: Sound to Sleep System will be turned on for the first two weeks of the study allowing the participant sleeping atop the mattress to feel the vibrations synced to the audio input. Sound to sleep system will be turned on during this phase of the study. The sound to sleep system will sync an audio input with the vibrations of the mattress technology and allow the user to control the intensity of the vibration.~No intervention: The mattress technology will be turned off for the second two weeks of the study. During this time, there will be no intervention.
- Mattress Technology Turned Off then On (Type: EXPERIMENTAL): No intervention: For the first two weeks of the study, the mattress technology will not be turned off. There will be no intervention during this time.~Intervention: Sound to Sleep System will be turned on for the second two weeks of the study allowing the participant sleeping atop the mattress to feel the vibrations synced to the audio input. Sound to sleep system will be turned on during this phase of the study. The sound to sleep system will sync an audio input with the vibrations of the mattress technology and allow the user to control the intensity of the vibration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies (HM) Receiving Treatment With Anti-Cluster of Differentiation (CD) 20 Monoclonal Antibodies (V212-013)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with a HM and is receiving treatment with anti-CD20 monoclonal antibodies and is not likely to undergo hematopoietic cell transplant (HCT).~* Has a predicted life expectancy of ≥ 12 months.~* Has prior history of varicella or antibodies to VZV due to exposure to the disease in a country where the disease is common.~* All female participants of childbearing potential must have a negative serum or urine pregnancy test.~Exclusion Criteria:~* A history of allergic reaction to any vaccine component (including gelatin) or an anaphylactic/anaphylactoid reaction to neomycin.~* Prior history of HZ within 1 year of enrollment.~* Prior receipt of any varicella or zoster vaccine.~* Participant is pregnant or breastfeeding or expecting to conceive within the period of 2 weeks prior to enrollment throughout 6 months after last vaccination dose.~* Any live virus vaccine administered or scheduled in the period from 4 weeks prior to Dose 1 through 28 days postvaccination dose 4.~* Any inactivated vaccine administered or scheduled within the period from 7 days prior to, through 7 days following, any dose of study vaccine.~* Participant is currently participating or has participated in a study with an investigational anti-CD20 monoclonal antibody within 3 months of signing informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- V212 (Type: EXPERIMENTAL): Participants receive V212 as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Email Campaign to Increase Uptake of myGeisinger

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Geisinger patients whose myGeisinger status is Pending, meaning an activation code has been generated for them, but they have not completed activation~Exclusion Criteria:~* Patients without email addresses on file~* Patients who received emails from this monthly myGeisinger marketing campaign within the last 2 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 88 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: None): A standard marketing message encouraging activation and describing the benefits of myGeisinger
- Focused on provider communication (Type: None): A simple message focused on one benefit of myGeisinger: communicating easily with providers
- Focused on scheduling (Type: None): A simple message focused on one benefit of myGeisinger: scheduling and managing appointments online
- Focused on medical information access (Type: None): A simple message focused on one benefit of myGeisinger: accessing medical information, like test results
- Social proof (Type: None): A message similar to control, but including information about how many other patients are using myGeisinger
- Endowment / decision staging (Type: None): A message similar to control, but framing myGeisinger as something that patients already have, and just need to take one more step to activate.~Endowment: Give patients the impression they already have the account, so they value it more.~Decision staging: Break down the process into multiple stages - having an account and activating that account- and giving the impression that they are almost there because the first stage is complete

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dietary Nitrate Supplements and Ischemic Stroke Recovery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years old and over~* Diagnosed with an ischemic stroke (acute focal neurological deficit resulting from an ischemic cause, verified by CT or MRI)~* Symptom onset within 5 days of admission~* National Institutes of Health Stroke Scale Score of 2 or more (but less than 20)~* A rating of fair or good on static sitting balance scale on a global balance scale~* A score of more that 0 on the hip flexion on the short Fugl-Myer~* Passed dysphagia screening for unrestricted or thickened liquids~Exclusion Criteria:~* Patients with severe stroke (National Institutes of Health Stroke Scale Score of 20 or more)~* A score of 0 on hip flexion on the Short Fugl-Myer as a result of weakness from the stroke~* A rating of poor on static sitting balance scale on a global balance scale~* Patients who received intravenous or intra-arterial recombinant tissue plasminogen activator (rtPA)~* Patients who are receiving citicoline~* Patients who have had a hemorrhagic stroke (including intraparenchymal, subarachnoid or subdural hemorrhage)~* A gait speed of more \> 0.8 m/s~* Patient with evidence of brain tumor or other psychiatric or neurological condition that would interfere with outcome measures~* Patients who will undergo carotid endarterectomy or other surgery during the study period~* Patients not living independently prior to stroke~* Survival is expected to be less than 6 months~* Any patient on organic nitrate-containing medications; some examples of the medications that are exclusions include nitroglycerin, isosorbide mononitrate, sildenafil (Viagra), and tadalafil (Cialis)~* Patients with atrophic gastritis~* Patients with hypotension (blood pressure less than 100/60 mmHg)~* Patients who do not pass the dysphagia screening test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Beet It Beetroot Juice (Type: EXPERIMENTAL): 70 cc (3.8 millimoles nitrate) Beet It organic beetroot juice once a day for 30 days. Vitamin C 500 mg (tablets) will be given along with each dose of the juice.
- Beet It Beetroot Juice Placebo (Type: PLACEBO_COMPARATOR): 70 cc Beet It organic beetroot juice (placebo) once a day for 30 days. The placebo beet juice is identical in appearance and taste with nitrate removed. Vitamin C 500 mg (tablets) will be given along with each dose of the juice.Beet It Placebo Beetroot juice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Currently receiving an antiretroviral regimen of E/C/F/TAF FDC (or emtricitabine \[FTC\]/TDF + 3rd agent if currently or previously participated in Study GS-US-292-1826 \[NCT02616783\]) for ≥ 3 months~* Documented plasma HIV-1 ribonucleic acid (RNA) \< 50 copies/mL during treatment with E/C/F/TAF (or FTC/TDF + 3rd agent if currently or previously participated in Study GS-US-292-1826 \[NCT02616783\]) for the last 2 visits preceding the screening visit (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL)~* Adequate renal function, an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min according to the Cockcroft-Gault formula for creatinine clearance~Key Exclusion Criteria:~* An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to screening~* Decompensated cirrhosis (eg, ascites, encephalopathy, or variceal bleeding)~* Current alcohol or substance use judged by the investigator to potentially interfere with participant study compliance~Note: Other protocol defined Inclusion/ Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- B/F/TAF (Type: EXPERIMENTAL): B/F/TAF FDC for at least 96 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult participants, ≥ 18 years of age.~* Locally advanced or recurrent (stage IIIB) or metastatic (stage IV) non-small cell lung cancer.~* Presence of epidermal growth factor receptor (EGFR) mutations in tumours.~* Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria.~* European Cooperative Oncology Group (ECOG) performance status ≤ 2.~Exclusion Criteria:~* Prior exposure to agents directed at the human epidermal receptor (HER) axis (eg, but not limited to erlotinib, gefitinib, cetuximab, or trastuzumab).~* Prior chemotherapy or systemic anti-neoplastic therapy for advanced disease.~* Lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome, or inability to take oral medication, or active gastroduodenal ulcer disease.~* Any inflammatory changes of the surface of the eye.~* ≥ Grade 2 peripheral neuropathy.~* History of any other malignancies within 5 years, except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer.~* Brain metastasis or spinal cord compression that has not yet been definitely treated with surgery and/or radiation, or treated but without evidence of stable disease for at least 2 months.~* Human immunodeficiency virus (HIV) infection.~* Pregnant, nursing, or lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erlotinib (Type: EXPERIMENTAL): Participants received erlotinib 150 mg orally once daily until progressive disease or unacceptable toxicity.
- Chemotherapy (Type: ACTIVE_COMPARATOR): Participants received gemcitabine 1250 mg/m\^2 intravenously (IV) on Days 1 and 8 and cisplatin 75 mg/m\^2 IV on Day 1 of every 3 week cycle until disease progression, unacceptable toxicity, or a total of 4 cycles, whichever came first.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: EvAluation of Clinical Effectiveness Of RoLenium Administered With Elpenhaler in Chronic Obstructive Pulmonary Disease (COPD) patientS in Daily Clinical Practice, in Greece

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients selected for treatment with the inhaled combination of propionic Fluticasone and Salmeterol (500+50)mcg - Rolenium- administered with Elpenhaler device~* FEV1 \<50% predicted normal (pre-bronchodilator),~* a history of repeated exacerbations who have significant symptoms despite regular bronchodilator therapy treated in Hospital outpatient specialist ward settings, in the daily clinical practice~* have signed informed consent~* be compliant with study procedures~Exclusion Criteria:~* - patients not selected for treatment with the inhaled combination of propionic~* FEV1 \>50% predicted normal (pre-bronchodilator),~* no history of repeated exacerbations~* not signed informed consent~* will not be compliant with study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: China-Administration of Nicorandil Group（CHANGE）

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Acute ST-T elevation MI patients (\<12h)~2. undergoing emergency PCI；~3. Subject has read and signed a written, informed consent form.~Exclusion Criteria:~1. SBP\<80mmHg；~2. LM stenosis~3. Aortic dissection；~4. AMI (\<6 month)~5. PCI或CABG (\<6 month)~6. Already under the treatment of Nicorandil；~7. Contraindicated or intolerable to Nicorandil~8. severe adverse effects to CMR or MRI；~9. Currently (or within one month) participating in another new drug trial.；~10. Pregnant or lactation period；~11. Severe somatic disease preventing the participant from completing the trial, or based on the discretion of the investigators, the patient is incapable of participating; Individuals with abnormal laboratory test results and/or clinical manifestations rendering them unsuitable to participate as judged by the investigators;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment arm (Type: EXPERIMENTAL): Patients were randomly assigned to two groups before emergent coronary angiography: those who received intravenous (iv.) nicorandil before and after (ivgtt.) reperfusion with PCI (nicorandil group);
- Placebo arm (Type: PLACEBO_COMPARATOR): Patients were randomly assigned to two groups before emergent coronary angiography, those who received placebo before and after reperfusion with PCI.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Home Evaluation of Exit Barriers in Wandering

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* veterans age 60 and over with an Alzheimer's-like dementia diagnosis, documented in medical record with International Codes for Diagnosis (ICD-9) codes that include all 290 diagnoses and 331.0~* Mini Mental State Examination (MMSE) 24 or less~* evidence of pre-elopement behaviors operationalized as scoring 1 standard deviation (SD) above mean on any one of the three items that comprise the Revised Algase Wandering Scale-Community Version (RAWS-CV) eloping subscale (#16 - He/she attempts to get outside; #27- He/she stands at the out door wanting to go out; #30- He/she attempts to find or go to familiar locations, even unrealistic ones)~* living in a non-institutional private family home or foster home~* independently ambulatory (with or without canes, walkers or wheelchairs to assist)~* living within a 60-mile radius of the James A. Haley Veterans Administration Medical Center (VAMC), Tampa, Florida~* living with a caregiver (CG) who is willing and able to serve as a study partner and provide informant reports, and who intends to be with the PDW for three months (allowing for being away for seven days or less during the three-month study period)~* English speaking.~Exclusion Criteria:~* living in a nursing home, group home or assisted living facility at point of entry (foster homes allowed)~* previous exposure to any visual exit barrier for wandering management~* no live-in CG~* bilaterally deaf or blind~* currently taking anti-psychotic medications~* current use of any visual exit barrier on any main exit doorway. CG will be allowed to use other wandering management interventions that are not specific to the exit doorways. For example, they may use a stop sign at the entrance to the kitchen, but may not use a stop sign on an experimentally monitored door.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Door Cover/Floor Cover (Type: EXPERIMENTAL): Baseline One (14 days), First Intervention (14 days), Baseline Two (14 days), Second Intervention (14 days)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Efficacy and Safety of On-demand Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Minimum of 12 months history of heartburn as the predominant symptom with at least 2 symptomatic episodes~* Negative endoscopy (no erosive lesions according to the Modified Savary-Miller scale) within 7 days prior to acute treatment~* at least 3 days with moderate to very severe heartburn within one week prior to acute treatment~Exclusion Criteria:~* No known gastro-duodenal ulcer~* no infections, inflammations, or obstruction of the small or large intestine~* no history of gastrointestinal cancer, or prior surgery of the stomach or intestine~* no stomach or abdominal pain or discomfort as the predominant symptom or that requires treatment~* no history of erosive reflux causing inflammation of the esophagus~* no stricture of the esophagus, stomach, or any condition that causes difficulty in swallowing~* no history of non-erosive reflux disease (NERD) that is or was refractory to an adequate treatment course (1 month) with proton pump inhibitors~* no females who are pregnant or those lacking adequate contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete